Results 31 to 40 of about 10,523 (190)

Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk.

PLoS ONE, 2022
Background and aimsThe LDL cholesterol (LDL-C) treatment goals recommended by the 2019 ESC/EAS guidelines are only achieved in a minority of patients. The study objective was to estimate the impact of bempedoic acid treatment on LDL-C target attainment ...
Julius L Katzmann, Christian Becker, Aikaterini Bilitou, Ulrich Laufs   +3 more
doaj   +1 more source

A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo

Journal of Lipid Research, 2022
Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibits the clearance of low-density lipoprotein (LDL) cholesterol (LDL-C) from plasma by directly binding with the LDL receptor (LDLR) and sending the receptor for lysosomal degradation.
Alexandra K. Suchowerska, Geurt Stokman, James T. Palmer, Phillip A. Coghlan, Elsbet J. Pieterman, Nanda Keijzer, Gilles Lambert, Kevin Chemello, Ali K. Jaafar, Jasneet Parmar, Liping Yan, Yingtao Tong, Lin Mu, Hans M.G. Princen, James Bonnar, Benny J. Evison   +15 more
doaj   +1 more source

Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes

Cardiovascular Diabetology, 2020
The proprotein convertase subtilisin/kexin type 9 (PCSK9) acts via a canonical pathway to regulate circulating low-density lipoprotein-cholesterol (LDL-C) via degradation of the LDL receptor (LDLR) on the liver cell surface.
Ying Tang, Sheng-Lan Li, Jia-Hui Hu, Kai-Jun Sun, Lei-Ling Liu, Dan-Yan Xu   +5 more
doaj   +1 more source

Acute Effect of Evolocumab on Lipoprotein(a) Level and Inflammation in Patients with Coronary Artery Disease

Journal of Cardiovascular Development and Disease, 2022
Background: Several studies have shown that high plasma lipoprotein(a) concentrations are associated with an increased risk of arteriosclerotic cardiovascular disease. Thus, Lp(a) has emerged as a new therapeutic target. Circulating proprotein convertase
Seung Woo Choi, Joan Kim, Gyeong Won Jang, Young Shin Lee, Jin Sun Park, Jung Myung Lee, Hyung Oh Kim, Hyemoon Chung, Jong Shin Woo, Woo Shik Kim, Weon Kim   +10 more
doaj   +1 more source

PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort

Biomedicine & Pharmacotherapy, 2022
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have emerged as a therapeutic option for patients with hypercholesterolemia who do not attain low-density lipoprotein cholesterol (LDL-C) goals and/or are intolerant to other lipid-lowering drugs.
Juan, Vicente-Valor, Xandra, García-González, Sara, Ibáñez-García, María Esther, Durán-García, Ana, de Lorenzo-Pinto, Carmen, Rodríguez-González, Irene, Méndez-Fernández, Juan Carlos, Percovich-Hualpa, Ana, Herranz-Alonso, María, Sanjurjo-Sáez   +9 more
openaire   +2 more sources

Control of dyslipidemia in the prevention of recurrent ischemic cerebrovascular accidents (expert opinion)

Неврология, нейропсихиатрия, психосоматика, 2022
On July 6, 2022, an interdisciplinary meeting of the Expert Council was held on the topic "Control of dyslipidemia in the prevention of acute and recurrent ischemic cerebrovascular accidents".
M. M. Tanashyan, N. A. Shamalov, I. A. Voznyuk, S. N. Yanishevsky, O. I. Vinogradov, D. R. Khasanova, O. V. Tikhomirova, V. A. Parfenov, E. V. Oshchepkova, M. V. Ezhov, V. S. Gurevich, V. V. Arkhipov   +11 more
doaj   +1 more source

PCSK9 inhibitors for LDL lowering [PDF]

Trends in Cardiovascular Medicine, 2015
In 2003, families were described with a rare, autosomal dominant form of familial hypercholesterolemia due to gain-of-function mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9) [1]. Subsequent studies demonstrated that PCSK9 is secreted from liver and accelerates degradation of LDL receptors [2,3].
openaire   +2 more sources

L-methionine promotes CD8+ T cells killing hepatocellular carcinoma by inhibiting NR1I2/PCSK9 signaling

Neoplasia: An International Journal for Oncology Research
Background: Liver cancer has consistently high incidence and mortality rates among malignant tumors. PCSK9, a target for hypercholesterolemia therapy, has recently been identified as an inhibitor of anti-tumor immunity, and targeting PCSK9 effectively ...
Chengsha Yuan, Changpeng Hu, Huyue Zhou, Wuyi Liu, Wenjing Lai, Yafeng Liu, Yue Yin, Guobing Li, Rong Zhang   +8 more
doaj   +1 more source

The Evolving Future of PCSK9 Inhibitors

Journal of the American College of Cardiology, 2018
Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies that target PCSK9 lower LDL cholesterol (LDL-C) levels by 55% to 72% in different high-risk patient groups.
Robert S, Rosenson, Robert A, Hegele, Sergio, Fazio, Christopher P, Cannon   +3 more
openaire   +2 more sources

Recent advances in the construction of humanized animal models and applications in translational medicine

Animal Models and Experimental Medicine, EarlyView.
Substantial advances have been achieved in the development of humanized mouse models, which have proven highly valuable in evaluating cancer immunotherapies and elucidating the mechanisms of infectious diseases. There is now a growing shift in research toward larger animal models—such as pigs—that offer greater physiological similarity to humans ...
Yanan Lyu, Yong‐Guang Yang, Zheng Hu
wiley   +1 more source